GNH USA

Europe — EMA

Idarubicin Accord Healthcare

GNH USA supplies Idarubicin Accord Healthcare (Idarubicin), an anthracycline antibiotic for acute myeloid and lymphoblastic leukemia.

Idarubicin Hydrochloride

Request sourcing

1
Pack/s

What is Idarubicin Hydrochloride?

Idarubicin, the active ingredient in Idarubicin Accord Healthcare, is an anthracycline antibiotic presented as an injectable solution for intravenous use. It intercalates into DNA and inhibits topoisomerase II, leading to cell death. The drug is indicated for the management of acute myeloid leukemia and acute lymphoblastic leukemia in adult patients.

GNH USA supplies Idarubicin Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing and regulatory support for oncology therapeutics.

What is Idarubicin Hydrochloride used for?

Idarubicin is an anthracycline used in the treatment of acute leukemias.

Acute Myeloid Leukemia: induces remission by targeting rapidly dividing leukemic blasts. Acute Lymphoblastic Leukemia: contributes to disease control through DNA damage in lymphoid blasts. Relapsed Acute Myeloid Leukemia: offers a therapeutic option when standard regimens have failed.

What are the side effects of Idarubicin Hydrochloride?

Idarubicin may cause a range of adverse reactions, varying from common chemotherapy‑related effects to serious, potentially life‑threatening events.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Fatigue - Mucositis (inflammation of the mouth lining)

Serious or Rare Side Effects: - Cardiotoxicity (irreversible heart damage) - Severe infections due to neutropenia - Secondary malignancies (therapy‑related cancers) - Acute pulmonary toxicity - Hepatotoxicity (liver injury)

What precautions apply to Idarubicin Hydrochloride?

Idarubicin requires careful monitoring and specific precautions to minimize risks.

Cardiac monitoring: assess baseline and periodic left ventricular function due to risk of cardiotoxicity. Hematologic monitoring: perform regular blood counts to detect myelosuppression. Drug interactions: review concomitant medications that may increase toxicity. Pregnancy and lactation: avoid use unless benefits outweigh risks; limited data are available. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Idarubicin Hydrochloride interact with?

Idarubicin can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Concurrent use with dexrazoxane: may reduce idarubicin efficacy. - Co‑administration with other cardiotoxic agents (e.g., doxorubicin, trastuzumab): increases risk of heart damage. - Strong CYP3A4 inhibitors: may raise idarubicin plasma concentrations.

Moderate Interactions (Monitor Closely): - Certain antimicrobials such as fluoroquinolones: may enhance myelosuppression. - Radiation therapy: may increase tissue toxicity when combined. - Electrolyte disturbances (hypokalemia, hypomagnesemia): heighten risk of cardiac arrhythmias.

Frequently asked questions

What is Idarubicin Accord Healthcare used for?+
Idarubicin Accord Healthcare is an injectable anthracycline chemotherapy used primarily to treat acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in adult patients. It works by destroying rapidly dividing leukemic cells, helping to achieve remission or disease control as part of established treatment protocols.
How does idarubicin work?+
Idarubicin exerts its antineoplastic effect by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and transcription. This blockade creates double‑strand DNA breaks, leading to apoptosis of malignant cells. The drug also generates free radicals that further damage cellular components, amplifying its cytotoxic activity.
What determines the dose of idarubicin?+
The dose of idarubicin is individualized by the prescribing oncologist based on factors such as the specific leukemia subtype, disease stage, patient body surface area, renal and hepatic function, and prior treatment history. Clinical guidelines provide dosing ranges, but the exact regimen is set by the treating physician to optimise efficacy while managing toxicity.
Is idarubicin safe in pregnancy or breastfeeding?+
Idarubicin is classified as contraindicated during pregnancy because it can cross the placenta and cause fetal harm, including teratogenic effects and embryotoxicity. Breastfeeding is also discouraged, as the drug may be excreted in milk and affect the infant. Use is only considered if the potential benefit to the mother outweighs the risks to the fetus or child, and only under specialist supervision.
How do I order Idarubicin Accord Healthcare from GNH USA?+
To place an order, visit the product page for Idarubicin Accord Healthcare on the GNH USA website (gnh-usa.com) and submit an enquiry with the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with any required import documentation.
How does idarubicin compare with other anthracyclines?+
Idarubicin is structurally related to other anthracyclines such as doxorubicin and daunorubicin but possesses a higher lipophilicity, which enhances cellular uptake and may provide greater potency against certain leukemias. Compared with doxorubicin, idarubicin often demonstrates a more favorable cardiac safety profile at equivalent doses, though all anthracyclines share risks of cardiotoxicity and myelosuppression. Choice of agent depends on disease characteristics, prior therapy, and individual patient risk factors.
What are the recommended storage conditions for Idarubicin Accord Healthcare?+
Idarubicin Accord Healthcare should be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F). The product must be kept in its original packaging to protect it from light, and it should never be frozen or shaken. If temperature excursions occur, the product should be inspected for any changes in appearance before use, and any compromised vials must be discarded according to local regulations.
How is Idarubicin administered?+
Idarubicin is given as an intravenous infusion, typically diluted in a compatible solution such as 5 % dextrose or normal saline. The infusion rate and duration are determined by the prescribing protocol, often over 30 minutes to several hours, and may be administered on specific days within a chemotherapy cycle. Administration should be performed by qualified healthcare professionals in a setting equipped to monitor for infusion‑related reactions and cardiac function.
What are the most serious risks to watch for with Idarubicin?+
The most critical risks associated with idarubicin include cardiotoxicity, which can manifest as reduced left‑ventricular ejection fraction or congestive heart failure, and severe myelosuppression leading to neutropenic infections, anemia, or bleeding. Additional serious concerns are the development of secondary malignancies and acute pulmonary toxicity. Patients should undergo regular cardiac assessments, complete blood counts, and close clinical monitoring to detect these complications early.
Who should not receive Idarubicin?+
Idarubicin is contraindicated in individuals with known hypersensitivity to idarubicin or any anthracycline component, those with pre‑existing severe cardiac disease, uncontrolled infections, or significant hepatic impairment that cannot be managed. Pregnant women and nursing mothers should avoid the drug unless the therapeutic benefit justifies the potential risk. Patients with a history of severe arrhythmias or who are receiving other cardiotoxic agents should also be evaluated carefully before treatment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Idarubicin Hydrochloride
Route
Intravenous Use
Manufacturer
Accord Healthcare Limited
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU